| Name | Title | Contact Details |
|---|
StageBio serves preclinical histology, pathology and specimen archiving clients in the biopharmaceutical, medical device and contract research industries.
M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.
Preferred Health Partners is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
Arkuda Therapeutics is a biotechnology company applying insights into lysosomal biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda`s lead program ARKD-104 aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer`s Disease and Parkinson`s Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, and Eli Lilly and Company.